N-{(1R,2R)-2-[2-(2-methoxy-5-methyl-4-piperazin-1-ylphenylamino)-5-trifluoromethylpyrimidin-4-ylamino]indan-1-yl}-N-methyl-methanesulphonamide | 1257259-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-{(1R,2R)-2-[2-(2-methoxy-5-methyl-4-piperazin-1-ylphenylamino)-5-trifluoromethylpyrimidin-4-ylamino]indan-1-yl}-N-methyl-methanesulphonamide
• 英文别名: N-[(1R,2R)-2-[[2-(2-methoxy-5-methyl-4-piperazin-1-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]amino]-2,3-dihydro-1H-inden-1-yl]-N-methylmethanesulfonamide
• CAS: 1257259-16-7
• 化学式: C₂₈H₃₄F₃N₇O₃S
• 分子量: 605.684
• InChiKey: DJGFKDJZOCFPPF-RCZVLFRGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• [EN] 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION<br/>[FR] 2, 4-DIAMINOPYRIMIDINES POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010136559A1

  公开（公告）日：2010-12-02

  The present invention encompasses compounds of general formula (1), wherein A, B, R1 to R5, Rx m, n and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and the use thereof [as] medicaments.

  本发明涵盖通式（1）的化合物，其中A，B，R1到R5，Rx m，n和p如权利要求1所定义，适用于治疗由过度或异常细胞增殖所特征的疾病，包含这样的化合物的制药配制物以及它们的用途作为药物。
• NEW CHEMICAL COMPOUNDS
  申请人：Sapountzis Ioannis

  公开号：US20110130401A1

  公开（公告）日：2011-06-02

  Compounds of general formula (1) wherein A, B, R 1 to R 5 , R x m, n and p are defined as described in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and the use thereof [as] medicaments.

  通式（1）中，A、B、R1至R5、Rxm、n和p的定义如规范所述，适用于治疗由过度或异常细胞增殖所特征的疾病，含有这种化合物的药物制剂和其用途作为药物。
• 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2435411B1

  公开（公告）日：2014-10-29
• US8410126B2
  申请人：——

  公开号：US8410126B2

  公开（公告）日：2013-04-02